Thomas KA Linden

Director/Government Chief Medical Officer

National Institute for Health and Welfare

Sweden

Research Interests

Explore related searches

Professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Thomas KA Linden serves as the Director and Government Chief Medical Officer at the National Board of Health and Welfare in Sweden. His research encompasses various critical areas, including the impact of P2Y12 receptor inhibitors on cognitive disorders post-stroke, as well as mortality trends among hospitalized COVID-19 patients. Linden's recent works also explore the relationship between early mobilization post-stroke and patient outcomes, and he examines the reliability of scoring in multicenter trials.

Articles (5)

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (2)

Sarah Johnson

Professor

University of Newcastle Australia

AUSTRALIA

View details

Kristoffer Strålin

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thomas KA Linden

Research Interests

Explore related searches

Contact this professor

About

Articles (5)

Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries

Mortality trends among hospitalised COVID-19 patients in Sweden: A nationwide observational cohort study

Mortality in hospitalized COVID-19 patients was associated with the COVID-19 admission rate during the first year of the pandemic in Sweden.

Fatal and Nonfatal Events Within 14 days After Early, Intensive Mobilization Poststroke.

The AVERT MoCA Data: Scoring Reliability in a Large Multicenter Trial

Collaborators (2)

Sarah Johnson

Kristoffer Strålin

Make your next move.